WEE1 and melanocytic neoplasm: Beyond melanoma, Class II and III MAP2K1 mutations have been identified in spitzoid, WNT-activated, protein kinase-activated, and BAP1-inactivated tumours, but reports of MAP2K1-driven melanocytic neoplasms without additional molecular alterations are scarce, with limited clinical follow-up.4